稳心颗粒配合右丙亚胺防治表柔比星心脏毒性的临床观察  

Wenxinkeli combined with dexrazoxane in the prevention of epirubicin-induced cardiotoxicity

作　　者：赵文娟[1] 赵伟[2] 

机构地区：[1]南方医科大学附属衡阳市中心医院急诊科,湖南衡阳421001 [2]中国医科大学附属第一医院肿瘤内科,辽宁沈阳110001

出　　处：《现代肿瘤医学》2013年第7期1623-1625,共3页Journal of Modern Oncology

摘　　要：目的:探讨稳心颗粒配合右丙亚胺对表柔比星所致心脏毒性的防治作用。方法:观察116例应用含表柔比星方案化疗的患者,以心电图的变化作为观察指标。先单独化疗4个周期,然后将已出现心电图异常者归入稳心颗粒配合右丙亚胺化疗组,心电图正常者分为单独化疗组与稳心颗粒配合右丙亚胺联合化疗组继续化疗2个周期,观察心电图变化。结果:单独化疗4个周期过程中,心电图异常发生率分别为24.1%(28/116)。继续化疗2个周期,单独化疗组心电图异常发生率分别为40.4%(21/52),稳心颗粒配合右丙亚胺化疗组心电图异常发生率为19.2%(10/52),(P<0.05),差异有统计学意义;稳心颗粒配合右丙亚胺治疗组有17.9%(5/28)患者异常心电图转为正常,有28.6%(8/28)患者异常心电图保持稳定,其余53.6%患者心脏损害加重。结论:稳心颗粒配合右丙亚胺对表柔比星所致心脏毒性的发生有一定的防治作用,使更多病人延长表阿霉素的治疗,并且对已经形成的心脏损害有一定的修复作用。Objective：To investigate the protective effects of Wenxinkeli with dexrazoxane on epirubicin cardiotoxicity.Methods：After four cycles of chemotherapyalone,116 patients were classified as a chemotherapy group and the Wenxinkeli with dexrazoxane combined with chemotherapygroup to observe the ECG changes after 2 cycles.Results：After four-cycles of chemotherapy alone,ECG abnormal incidence was 24.1%（28/116）.To proceed two cycles of chemotherapy,the incidence of ECG abnormalities was 40.4%（21/52）in chemotherapy alone group and 19.2%（10/52）in the Wenxinkeli with dexrazoxane combined group.The difference was significant（P0.05）.In Wenxinkeli with dexrazoxane treatment group,there was 17.9%（5/28）patients whose ECG charged from abnormal to normal,and 28.6%（8/28）remained stable.The heart damage of remaining 53.6% patients increased.Conclusion：Wenxinkeli combined with dexrazoxane not only has cardiao-protective activtyagainst cardio-toxicity induced and enable more patients to extend the treatment of epirubicin by epirubicin but also has some therapeutic effect.

关 键 词：右丙亚胺 表柔比星 心脏毒性 

分 类 号：R730.53[医药卫生—肿瘤]